|
Hovione is a Portuguese company that produces active pharmaceutical ingredients (APIs) and conducts drug product intermediates development and compliant manufacture. It has sites in the United States, Portugal, Ireland and China. The company provides a number of products and services to the pharmaceutical industry including separate or integrated API, pre-formulated compounds, particle engineering, formulation development and manufacturing. It also supports highly potent compounds and proprietary product development and licensing for drug products. It is also present in the inhalation area. == History == Hovione continues to be a privately held company with 5 plants - in Portugal (1969), Macao (1986), New Jersey (2001), Taizhou in mainland China (2008) and Cork, Ireland (2009) - have a total reactor capacity of 1300 m³ and 1100 people worldwide. Since Hovione started operations in 1959, the company has patented more than 100 innovative chemical processes and produced industrially over 45 different APIs. All Hovione sites have been successfully inspected either by FDA, European Medicines Agency or the PMDA Japanese agency.〔(Fine Chemicals: The Industry and the Business – 2nd Edition, Wiley 2012 )〕〔( EPM Magazine )〕〔( “How to avoid icebergs” – Speciality Chemicals Magazine )〕〔( “A test tube in three continents” - Macao Magazine )〕 Hovione is a major source of semi-synthetic tetracyclines and corticosteroids, and is the largest independent supplier of contrast agents – these three families of compounds make up most of its generic product portfolio. The other half of the business focuses on exclusive projects:〔( “Handling potent drug materials” – Clean Room Technology )〕〔( “What is special about inhalation APIs?” - Drug Delivery Technology )〕 * Development and manufacture of innovator APIs * Particle Engineering: manipulations of physical properties of APIs, polymeric encapsulation * Development of formulations for pulmonary delivery 抄文引用元・出典: フリー百科事典『 ウィキペディア（Wikipedia）』 ■ウィキペディアで「Hovione」の詳細全文を読む スポンサード リンク
|